---
title: "Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. (002399.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002399.SZ.md"
symbol: "002399.SZ"
name: "Shenzhen Hepalink Pharmaceutical Group Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T18:47:24.513Z"
locales:
  - [en](https://longbridge.com/en/quote/002399.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002399.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002399.SZ.md)
---

# Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. (002399.SZ)

## Company Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hepalink.com](https://www.hepalink.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.47)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 86 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.15% |  |
| Net Profit YoY | -41.31% |  |
| P/B Ratio | 1.25 |  |
| Dividend Ratio | 2.40% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15287023355.23 |  |
| Revenue | 5425207931.50 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.11% | C |
| Profit Margin | 7.03% | B |
| Gross Margin | 34.15% | C |
| Revenue YoY | 2.15% | C |
| Net Profit YoY | -41.31% | D |
| Total Assets YoY | -3.04% | D |
| Net Assets YoY | -0.90% | D |
| Cash Flow Margin | 406.25% | A |
| OCF YoY | 2.15% | C |
| Turnover | 0.31 | D |
| Gearing Ratio | 28.12% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.15%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-41.31%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.25",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.40%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "15287023355.23",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5425207931.50",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.11%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.03%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "34.15%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "2.15%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-41.31%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.04%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.90%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "406.25%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "2.15%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.31",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "28.12%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 39.30 | 89/215 | 43.34 | 41.92 | 29.90 |
| PB | 1.23 | 19/215 | 1.49 | 1.43 | 1.38 |
| PS (TTM) | 2.76 | 66/215 | 3.42 | 3.29 | 3.10 |
| Dividend Yield | 2.45% | 53/215 | 2.20% | 2.08% | 1.99% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-05T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Sell | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.19 |
| Highest Target | 8.30 |
| Lowest Target | 8.30 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002399.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002399.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002399.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002399.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**